Illumina, Inc. Company Profile
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
News Articles
Roche-VRP: Übernahme von Illumina ist definitiv vom Tisch
Zürich - Roche-Verwaltungsratspräsident Franz Humer erteilt den Gerüchten um einen erneuten Übernahmeversuch von Illumina eine Abfuhr. "Illumina ist endgültig vom Tisch". Die Gegenseite sei nicht...
Roche Bids Again for Illumina?
Bloomberg | A Swiss newspaper is reporting that Roche and Illumina may have come to a purchase agreement, eight months after Illumina rejected Roche's last proposed bid. The two companies will announ...
Illumina Joins $41M Bet on Oxford Nanopore
San Diego-based Illumina (NASDAQ: ILMN), the world’s biggest maker of high-speed gene sequencing machines, has made another equity investment in U.K-based Oxford Nanpore. Oxford said today it ha...
Illumina Offered the Counter Bid for Complete Genomics
Bloomberg | As suspected by many, Illumina says it was the second bidder for Complete Genomics. Complete rejected Illumina's offer--a 5% premium over the BGI offer--because the deal would have likely...
Eurofins MWG Operon reinforces NGS capability with Illumina HiSeq 2500 and Illumina MiSeq
(Eurofins MWG Operon) Eurofins MWG Operon, one of the pioneers and key providers of next generation sequencing (NGS), has added an Illumina HiSeq 2500 and an Illumina MiSeq sequencer to its fleet of...
Illumina-Aktien reagieren positiv auf geplatzte Übernahme
Die Aktien des Gentechnikspezialisten Illumina haben positiv auf die geplatzte Übernahme durch Roche reagiert. Der Pharmariese versuchte über Monate, Illumina zu übernehmen. Nun gab Franz Humer, VR...
Illumina, Life Technologies Forge Rival Partnerships to Implement Clinical Genomics Networks
Bio-IT World | The two giants of next-generation sequencing technology, Illumina and Life Technologies, have announced rival initiatives with leading medical institutions in Boston to further the inte...
Partners HealthCare, Illumina announce founding members of GeneInsight Network
Partners HealthCare, a Boston-based integrated health system, and Illumina, a developer, manufacturer and marketer of life science tools and integrated systems, announced the GeneInsight-Illumina Foun...
Drugs and Medications
None
PubMed Articles
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.
Whole genome and exome sequencing of matched tumor-normal sample pairs is becoming routine in cancer research. The consequent increased demand for somatic variant analysis of paired samples requires m...
De novo assembly of short sequence reads.
A new generation of sequencing technologies is revolutionizing molecular biology. Illumina's Solexa and Applied Biosystems' SOLiD generate gigabases of nucleotide sequence per week. However, a perceiv...
HTQC: a fast quality control toolkit for Illumina sequencing data.
ABSTRACT: BACKGROUND: Illumina sequencing platform is widely used in genome research. Sequence reads quality assessment and control are needed for downstream analysis. However, software that provides...
Sequencing bias: comparison of different protocols of MicroRNA library construction.
ABSTRACT: BACKGROUND: MicroRNAs(miRNAs) are 18-25 nt small RNAs playing critical roles in many biological processes. The majority of known miRNAs were discovered by conventional cloning and a Sanger s...
A SNP resource for Douglas-fir: de novo transcriptome assembly and SNP detection and validation.
BACKGROUND: Douglas-fir (Pseudotsuga menziesii), one of the most economically and ecologically important tree species in the world, also has one of the largest tree breeding programs. Although the coa...
Clinical Trials
None
Companies
Illumina develops tools for the large-scale analysis of genetic variation and function, the results of which will pave the way for personalized medicine, a key goal of genomics and proteomics. Our tec...
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and...
Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichmen...
"imaGenes is a premier provider of genome research services in Europe and was founded in 2007 as a spin-off from RZPD (German Resource Center for Genome Research). imaGenes manages one of the most com...
Headquartered in Ramsey, Minn., Vision-Ease Lens is a manufacturer of quality ophthalmic lenses including LifeRx® light-responsive lenses, Coppertone⢠polarized lenses, Su...
More Information about "Illumina, Inc." on BioPortfolio
We have published hundreds of Illumina, Inc. news stories on BioPortfolio along with dozens of Illumina, Inc. Clinical Trials and PubMed Articles about Illumina, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Illumina, Inc. Companies in our database. You can also find out about relevant Illumina, Inc. Drugs and Medications on this site too.
